Top

Published in:

01-03-2011 | Research Paper

Expression and significance of HER family receptors in neuroblastic tumors

Authors: Ewa Izycka-Swieszewska, Agnieszka Wozniak, Elzbieta Drozynska, Jacek Kot, Wieslawa Grajkowska, Teresa Klepacka, Danuta Perek, Sylwia Koltan, Ewa Bien, Janusz Limon

Published in: Clinical & Experimental Metastasis | Issue 3/2011

Abstract

HER receptor family plays an important role in normal embryonic development and is involved in pathogenesis and progression of some types of cancer. Neuroblastic tumors (NT) are common pediatric neoplasms with a poor outcome in a significant number of patients. The biological and prognostic role of HER family in NT is not well established. In the current study we evaluated HER1–4 receptors expression, their prognostic significance and clinicopathological correlations in a series of 103 NTs by immunohistochemical assessment of HER1–4 expression and FISH analysis of EGFR and HER2 copy number status. HER receptors are commonly expressed in NT but it was not due to EGFR or HER2 amplification. EGFR, HER2 and HER4 show correlation with tumor histology. It seems that these receptors take part in neuroblastic cell differentiation and Schwannian stroma development. EGFR and HER2 positivity are more frequently found in favorable histological risk group of tumours (P = 0.004 and P = 0.01 respectively) while high expression of HER4 is significantly more often found in patients with metastatic disease (P = 0.03). Moreover tumors with HER2 polysomy were more often found in children ≤18 months, with localized disease, and favorable histological group. Our study showed that the role of HER family members in NT biology is interrelated and complex but their expression level may present a novel prognostic factor for NT patients outcome.

Brodeur G (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3:203–216CrossRefPubMed

Maris J, Hogarty M, Bagatell R, Cohn S (2007) Neuroblastoma. Lancet 369:2106–2120CrossRefPubMed

Nakagawara A (2004) Neural crest development and neuroblastoma: the genetic and biological link. Prog Brain Res 146:233–242PubMed

Mosse YP, Laudenslager M, Longo L, Maris J (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455:930–935CrossRefPubMed

Shimada H, Ambros I, Dehner L et al (1999) The international neuroblastoma pathology classification (the Shimada system). Cancer 86:364–372CrossRefPubMed

Joshi W, Silverman J, Altshuler G et al (1993) Systematization of primary histopathologic and fine-needle aspiration cytologic features and description of unusual histopathologic feature of neuroblastic tumors: a report from the Pediatric Oncology Group. Hum Pathol 24:493–504CrossRefPubMed

Cohn S, Pearson A, London W et al (2009) The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol 27:289–297CrossRefPubMed

Fong A, Park J (2009) High-risk neuroblastoma: a therapy in evolution. Pediatr Hematol Oncol 26:539–548CrossRefPubMed

Jakacki R, Hamilton M, Gilbertson R et al (2008) Pediatric phase I and pharmacokinetic study of Erlotinib followed by the combination of Erlotinib and Temozolomid: a children’s oncology group phase I consortium study. J Clin Oncol 26:4921–4927CrossRefPubMed

10.

Vermuelen J, De Preter K, Naranjo A et al (2009) Predicting outcomes for children with neuroblastoma using a multigene expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 10:663–671CrossRef

11.

Baselga J, Swain S (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463–475CrossRefPubMed

12.

Citri A, Yarden Y (2006) EGF-ERBB signaling: towards the systems level. Nat Rev Mol Cell Biol 7:505–516CrossRefPubMed

13.

Zaczek A, Brandt B, Bielawski KP (2005) The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 20:1005–1015PubMed

14.

Britsch S, Li L, Kirchhoff S et al (1998) The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. Genes Dev 12:1825–1836CrossRefPubMed

15.

Casalini P, Iorio M, Galmozzi E, Menard S (2004) Role of HER receptors family in development and differentiation. J Cell Physiol 200:343–350CrossRefPubMed

16.

Chan R, Hardy W, Laing M, Hardy S, Muller W (2002) The catalytic activity of the ErbB2 receptor tyrosine kinase is essential for embryonic development. Mol Cell Biol 22:1073–1078CrossRefPubMed

17.

Ganti R, Skapek S, Zhang J et al (2006) Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Modern Pathol 19:1213–1220CrossRef

18.

Ho R, Minturn J, Hishiki T et al (2005) Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 65:9868–9875CrossRefPubMed

19.

Richards KN, Zweidler-McKay PA, Van Roy N et al (2010) Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer 116:3233–3243CrossRefPubMed

20.

Qualman S, Bowen J, Fitzgibbons P et al (2005) Protocol for the examination of specimens from patients with neuroblastoma and related neuroblastic tumors. Arch Pathol Lab Med 129:874–883PubMed

21.

Izycka-Swieszewska E, Wozniak A, Kot J et al (2010) Prognostic significance of HER2 expression in neuroblastic tumors. Mod Pathol 23:1261–1268CrossRefPubMed

22.

Corzo C, Bellosillo B, Corominas J et al (2007) Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase IIα expression. Tumor Biol 28:221–228CrossRef

23.

Varella-Garcia M (2006) Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 1:19CrossRefPubMed

24.

Vandensompele J, Baudis M, De Preter K et al (2005) Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 23:2280–2299CrossRef

25.

Gilbertson RJ (2005) ERBB2 in pediatric cancer: innocent until proven guilty. Oncologist 10:508–517CrossRefPubMed

26.

Rogers S, Harrington K, Rhys-Evans P et al (2005) Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 24:47–69CrossRefPubMed

27.

Layfield L, Thompson K, Dodge R, Kerns B (1995) Prognostic indicators for neuroblastoma: stage, grade, DNA ploidy, MIB-1-proliferation index, p53, HER-2/neu and EGFR—a survival study. J Surg Oncol 59:21–27CrossRefPubMed

28.

Tamura S, Hosoi H, Kuwahara Y et al (2007) Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. BBRC 358:226–232PubMed

29.

Rossler J, Odenthal E, Geoerger B et al (2009) EGFR inhibition using Gefitinib is not active in neuroblastoma cell lines. Anticancer Res 29:1327–1334PubMed

30.

Chiu B, Mirkin B, Madonna M (2007) Epidermal growth factor can induce apoptosis in neuroblastoma. Mitogenic and apoptotic actions of EGF on neuroblastoma cells are concentration-dependent. J Ped Surg 42:482–488CrossRef

31.

Tovey S, Reeves J, Stanton P, Ozanne B, Barlett J, Cooke T (2006) Low expression of HER2 protein in breast cancer is biologically significant. J Pathol 210:358–362CrossRefPubMed

32.

Goji J, Nakamura H, Ito H, Mabuchi O, Hashimoto K, Sano K (1995) Expression of c-ErbB2 in human neuroblastoma tissues, adrenal medulla adjacent to tumor, and developing mouse neural crest cells. Am J Pathol 146:660–672PubMed

33.

Gambini C, Sementa AR, Boni L et al (2003) Expression of HER2/neu is uncommon in human neuroblastic tumors and is unrelated to tumor progression. Cancer Immunol Immunother 52:116–120PubMed

34.

Hayashi M, Inokuchi M, Takagi Y et al (2008) High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res 14:7843–7849CrossRefPubMed

35.

Witton C, Reeves J, Going J, Cooke T, Barlett J (2003) Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer. J Pathol 200:290–297CrossRefPubMed

36.

Srinivasan R, Poulsom R, Hurst H, Gullick W (1998) Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumor types. J Pathol 185:236–245CrossRefPubMed

37.

Muraoka-Cook R, Sandahl M, Husted C et al (2006) The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol Biol Cell 17:4118–4129CrossRefPubMed

Title: Expression and significance of HER family receptors in neuroblastic tumors
Authors: Ewa Izycka-Swieszewska
Agnieszka Wozniak
Elzbieta Drozynska
Jacek Kot
Wieslawa Grajkowska
Teresa Klepacka
Danuta Perek
Sylwia Koltan
Ewa Bien
Janusz Limon
Publication date: 01-03-2011
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 3/2011
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-010-9369-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

IFN-γ is essential for the inhibition of B16BL6 melanoma lung metastasis in chronic alcohol drinking mice

Alterations of the retinoblastoma gene in metastatic breast cancer

The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis

Tetraspanins and tumor progression

Is gastrointestinal dysfunction induced by gastric cancer peritoneal metastasis relevant to impairment of interstitial cells of Cajal?

Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992–2008

Keynote webinar | Spotlight on antibody–drug conjugates in cancer